Dianthus Unveils DNTH312, a First-in-Class Bifunctional Autoimmune Therapy
DNTH has more than doubled off its 52-week low of $18.08.
Summary
Dianthus announced DNTH312, a new internally developed bifunctional fusion protein that combines its lead asset claseprubart with TACI to simultaneously inhibit the classical complement pathway and B-cell activity. Preclinical data show comparable potency to claseprubart and similar immunoglobulin reductions to povetacicept, with a half-life supporting infrequent subcutaneous dosing. The company aims to be Phase 1 ready by year-end 2027, extending its neuromuscular franchise with IP protection through at least 2047. This follows positive Phase 3 interim data for claseprubart in June and a strong cash position from a $777.7 million raise, providing runway into 2030. The new candidate broadens the pipeline into additional autoimmune indications like lupus and Sjögren's, potentially increasing the addressable market.
At the time of this announcement, DNTH was trading at $106.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $18.08 to $114.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.